Day One Biopharmaceuticals reported Q2 2025 net product revenue of $33.6 million for OJEMDA, a 10% increase over Q1.
Net cash used in operating activities decreased by approximately 50% quarter-over-quarter.
The company ended Q2 with $453 million in cash and no debt.
Total costs and operating expenses were $68.9 million in Q2, including $10.9 million in noncash stock-based compensation, representing a 5% decrease quarter-over-quarter.
Adjusted EBITDA margin for legacy Globus was 32.3%, up 210 basis points from prior year quarter; Nevro finished near breakeven adjusted EBITDA.
Free cash flow was $31.3 million, growing 18% despite higher CapEx and acquisition impacts; operating cash flow was $77.9 million.
GAAP gross profit improved to 63.3% from 55.2% prior year, driven by lower inventory step-up amortization; adjusted gross profit was 67.4%.
Globus Medical reported Q2 2025 revenue of $745.3 million, an 18.4% increase year-over-year, including $94.6 million from the Nevro acquisition.
Legacy Globus business revenue grew 3.3% as reported and 4.9% on a day-adjusted basis, driven primarily by U.S. Spine and trauma segments.
Non-GAAP EPS grew 14.1% to $0.86, with GAAP EPS at $1.49, boosted by a $110.6 million bargain purchase gain from Nevro acquisition.
R&D expenses decreased to 5.4% of sales from 6%, reflecting synergy capture and lower headcount in legacy Globus.
SG&A expenses increased to 40.7% of sales due to higher sales compensation, third-party spend, and employee benefits, partially offset by lower bad debt.
Dafinchi